risperidone has been researched along with chlorpromazine in 109 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 13 (11.93) | 18.2507 |
2000's | 57 (52.29) | 29.6817 |
2010's | 34 (31.19) | 24.3611 |
2020's | 5 (4.59) | 2.80 |
Authors | Studies |
---|---|
Baldy, WJ; Barrett, DL; DiStefano, DL; Elgin, RJ; Fedde, CL; Kesslick, JM; Kukla, MJ; Martin, GE; Mathiasen, JR; Scott, MK | 1 |
Choudhary, MS; Craigo, SC; Meltzer, HY; Monsma, FJ; Roth, BL; Shen, Y; Sibley, DR; Uluer, A | 1 |
Druck, T; Hamblin, MW; Huebner, K; Khan, N; Kohen, R; Lachowicz, JE; Meltzer, HY; Metcalf, MA; Roth, BL; Sibley, DR | 1 |
Egan, CT; Herrick-Davis, K; Teitler, M | 1 |
Audinot, V; Chaput, C; Conte, C; Gavaudan, S; Millan, MJ; Newman-Tancredi, A; Touzard, M; Verrièle, L | 1 |
Topliss, JG; Yoshida, F | 1 |
Grinde, E; Herrick-Davis, K; Teitler, M | 1 |
Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA | 1 |
Boulton, DW; DeVane, CL; Liston, HL; Markowitz, JS | 1 |
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 2 |
Cavalli, A; De Ponti, F; Poluzzi, E; Recanatini, M | 1 |
Ernsberger, P; Hufeisen, SJ; Jayathilake, K; Kroeze, WK; Meltzer, HY; Popadak, BA; Renock, SM; Roth, BL; Steinberg, S | 1 |
Glennon, RA | 1 |
Keserü, GM | 1 |
Li, J; Rajamani, R; Reynolds, CH; Tounge, BA | 1 |
Herrick-Davis, K; Purohit, A; Smith, C; Teitler, M | 1 |
Bergström, F; Giordanetto, F; Rehngren, M; Tunek, A; Wan, H | 1 |
Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
Coolen, HK; Glennon, JC; Kruse, CG; Lange, JH; Reinders, JH; Tolboom, JT | 1 |
Farasati, NA; Huang, Y; Randhawa, P | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Jia, L; Sun, H | 1 |
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Caron, G; Ermondi, G; Visentin, S | 1 |
Ahman, M; Holmén, AG; Wan, H | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Boriss, H; Braggio, S; Corbioli, S; Fontana, S; Helmdach, L; Longhi, R; Schiller, J; Vinco, F | 1 |
Sen, S; Sinha, N | 1 |
Cooper, J; Cui, Y; Fink, M; Gavaghan, DJ; Heath, BM; McMahon, NC; Mirams, GR; Noble, D; Sher, A | 1 |
Caradonna, NP; Hallifax, D; Houston, JB; Turlizzi, E; Zanelli, U | 1 |
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Dalvie, D; Loi, CM; Smith, DA | 1 |
Brown, AM; Bruening-Wright, A; Kramer, J; Kuryshev, YA; Myatt, G; Obejero-Paz, CA; Verducci, JS | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Bellman, K; Knegtel, RM; Settimo, L | 1 |
Bienkowski, P; Bucki, A; Jaśkowska, J; Kazek, G; Kowalski, P; Kołaczkowski, M; Marcinkowska, M; Mierzejewski, P; Mitka, K; Pawłowski, M; Siwek, A; Wasik, A; Wesołowska, A | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Freeman, BB; Rankovic, Z; Yang, L | 1 |
Aghajanian, GK; Gellman, RL | 1 |
Auchus, AP; Freeman, A; Green, RC | 1 |
DeVane, CL | 1 |
Conway, PC; Corbett, R; Dunn, RW; Hartman, H; Helsley, GC; Kerman, LL; Strupczewski, JT; Woods, AT | 1 |
Matsubara, R | 1 |
Finlayson, A; Johnstone, EC; Mercer, G; Murray, C; Owens, DG | 1 |
Ervine, CM; Hughes, AM; Lynch, P; Rhodes, J; Yates, RA | 1 |
McCallum, SE; Porter, JH; Vann, RE; Varvel, SA | 1 |
Kameda, K; Koyama, T; Kusumi, I; Suzuki, K; Takahashi, Y | 1 |
Hori, M; Hori, T; Kawanishi, Y; Shiraishi, H; Suzuki, T; Tachikawa, H | 1 |
Nomikos, GG; Rodriguez, DE; Shirazi-Southall, S | 1 |
Hägg, S; Hedenmalm, K; Mortimer, O; Spigset, O; Ståhl, M | 1 |
Goudie, AJ; Smith, JA | 1 |
Kamijo, Y; Kurihara, K; Nagai, T; Ohwada, T; Soma, K | 1 |
Kalkman, HO; Loetscher, E | 1 |
Dhawan, BN; Kumar, R; Palit, G | 1 |
Woods, SW | 1 |
Morishita, S | 1 |
Burnet, PW; Harrison, PJ; Hutchinson, LJ; Law, AJ | 1 |
Matsuoka, N; Mutoh, S; Shirakawa, K; Tada, M | 1 |
Barrett, SL; Bell, R; King, DJ; Watson, D | 1 |
Girimaji, SC; Jairam, R; Seshadri, SP; Srinath, S | 1 |
Lawrie, S; McIntosh, A; Nadeem, Z | 2 |
Lawrie, S; McIntosh, A | 1 |
Adams, AS; Kanavos, P; Park, S; Ross-Degnan, D; Sabin, J; Soumerai, SB | 1 |
Liu, W; Mou, XD; Shi, JB; Sun, J; Yao, ZJ; Zhang, XR; Zhang, ZJ | 1 |
Balit, CR; Isbister, GK; Kilham, HA | 1 |
Mahadik, SP; Pillai, A; Terry, AV | 1 |
Mahadik, SP; Parikh, V; Pillai, A; Terry, AV | 1 |
Bastianetto, S; Danik, M; Mennicken, F; Quirion, R; Williams, S | 1 |
Chen, CD; Kao, WT; Lung, FW; Tung, YP; Wang, CS | 1 |
DeVane, CL; Donovan, JL; Markowitz, JS; Wang, JS; Zhu, HJ | 1 |
Boshoven, W; Duncan, E; Dunlop, BW; Hamer, RM; Phillips, LS; Woolson, SL | 1 |
Dierks, T; Irisawa, S; Isotani, T; Kikuchi, M; Kinoshita, T; Koenig, T; Okugawa, G; Strik, W; Yagyu, T; Yamada, K; Yoshimura, M | 1 |
Eberhard, J; Holstad, M; Levander, S; Lindström, E | 1 |
Bishnoi, M; Chopra, K; Kulkarni, SK; Kumar, A | 1 |
Jin, GX; Tong, Y; Wang, XP; Wang, XY; Yao, SM; Zhang, ZJ | 1 |
Carlsson, A; Stening, G; Timdahl, K | 1 |
Cooper, T; Usubiaga, H; Winsberg, B | 1 |
Athey, R; Forlano, R; Singh, D | 1 |
Buyukoglan, H; Kaya, MG; Ulusoy, HB; Yagmur, F | 1 |
Jayaram, MB; Rattehalli, RD; Sivaraman, P | 1 |
Bogdan, F; Bogdan, M; Popescu, F | 1 |
Diefenderfer, LA; Iuppa, CA | 1 |
Elmorsy, E; Elsheikha, HM; Elzalabany, LM; Smith, PA | 1 |
De Luca, MA; Di Chiara, G; Perra, V; Serra, GP; Tanda, G; Valentini, V | 1 |
Babigumira, JB; Lubinga, SJ; Mutamba, BB; Nganizi, A | 1 |
He, L; Huang, H; Li, M; Minica, C; Qin, S; Shen, L; Shi, Y; Wang, G; Wu, X; Xing, Q; Xu, Q; Yi, Z | 1 |
Baytunca, MB; Erermis, S; Kose, S; Ozbaran, B | 1 |
Lee, SY; Lee, TL; Shyu, YC; Wang, LJ; Yang, CJ; Yang, KC; Yuan, SS | 1 |
Bo, L; Saha, KB; Sampson, S; Xia, J; Zaman, RU; Zhao, S | 1 |
Ino, H; Ishige, M; Iyo, M; Kanahara, N; Kimura, H; Komatsu, H; Komatsu, N; Muneoka, K; Sasaki, T; Shimizu, E; Suzuki, T; Watanabe, H; Yamanaka, H; Yoshimura, K | 1 |
Bielecka-Wajdman, AM; Nowacka, M; Obuchowicz, E; Paul-Samojedny, M | 1 |
Arasappa, R; Chand, PK; Kulkarni, K; Muralidharan, K; Murthy, P; Philip, M; Prasad M, K; Zutshi, A | 1 |
Deng, H; Xu, J | 1 |
Aggour, AM; Al-Ghafari, A; Amer, S; Elmorsy, E; Khan, R | 1 |
Blessing, EM; Blessing, WW; Mohammed, M; Ootsuka, Y | 1 |
Hirai, T; Kose, E; Seki, T; Yasuno, N | 1 |
Basu, B; John Jayakumar, JAK; Panicker, MM | 1 |
Aguglia, E; Amore, M; Bellomo, A; Bertolino, A; Cascino, G; Collantoni, E; Corrivetti, G; Cuomo, A; D'Ambrosio, E; Dell'Osso, L; Frascarelli, M; Galderisi, S; Giordano, GM; Giuliani, L; Maj, M; Marchesi, C; Monteleone, AM; Monteleone, P; Montemagni, C; Oldani, L; Pinna, F; Pompili, M; Rocca, P; Roncone, R; Rossi, A; Rossi, R; Siracusano, A; Vita, A; Zeppegno, P | 1 |
Sood, S | 1 |
Osman, E; Yıldız, M | 1 |
14 review(s) available for risperidone and chlorpromazine
Article | Year |
---|---|
Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7).
Topics: Animals; Humans; Ligands; Receptors, Serotonin; Serotonin Agents; Serotonin Antagonists; Serotonin Receptor Agonists | 2003 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Practical approaches to evaluating and optimizing brain exposure in early drug discovery.
Topics: Animals; Blood-Brain Barrier; Central Nervous System; Central Nervous System Agents; Drug Delivery Systems; Drug Discovery; Humans; Molecular Structure; Structure-Activity Relationship | 2019 |
Brief comparison of the pharmacokinetics and pharmacodynamics of the traditional and newer antipsychotic drugs.
Topics: Antipsychotic Agents; Chlorpromazine; Clozapine; Haloperidol; Humans; Isoxazoles; Piperidines; Risperidone; Time Factors | 1995 |
Chlorpromazine equivalent doses for the newer atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chlorpromazine; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Haloperidol; Humans; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Therapeutic Equivalency; Thiazoles | 2003 |
[Late schizophrenia].
Topics: Adult; Age of Onset; Aged; Antipsychotic Agents; Chlorpromazine; Clozapine; Diagnostic and Statistical Manual of Mental Disorders; Electroconvulsive Therapy; Haloperidol; Humans; Middle Aged; Reference Standards; Risk Factors; Risperidone; Schizophrenia; Schizophrenic Psychology | 2003 |
Schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Clozapine; Cognitive Behavioral Therapy; Dibenzothiepins; Haloperidol; Humans; Olanzapine; Patient Compliance; Perazine; Pimozide; Risperidone; Schizophrenia; Sulpiride | 2003 |
Schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Clozapine; Haloperidol; Humans; Olanzapine; Patient Compliance; Perazine; Pimozide; Risperidone; Schizophrenia; Sulpiride | 2004 |
Antipsychotic poisoning in young children: a systematic review.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Child, Preschool; Chlorpromazine; Clozapine; Dibenzothiazepines; Haloperidol; Humans; Infant; Infant, Newborn; Olanzapine; Pimozide; Piperazines; Poisoning; Quetiapine Fumarate; Quinolones; Risperidone | 2005 |
Schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Chlorpromazine; Clozapine; Cognitive Behavioral Therapy; Dibenzothiepins; Family Therapy; Haloperidol; Humans; Patient Compliance; Risperidone; Schizophrenia; Secondary Prevention; Sulpiride; Thioridazine | 2005 |
An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Dibenzothiazepines; Female; Haloperidol; Humans; Incidence; Male; Middle Aged; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia | 2007 |
Levomepromazine for schizophrenia.
Topics: Antipsychotic Agents; Chlorpromazine; Humans; Methotrimeprazine; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia | 2010 |
Chlorpromazine versus atypical antipsychotic drugs for schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Humans; Olanzapine; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia | 2016 |
Wendan decoction (Traditional Chinese medicine) for schizophrenia.
Topics: Antipsychotic Agents; Chlorpromazine; Drug Therapy, Combination; Drugs, Chinese Herbal; Dyskinesia, Drug-Induced; Humans; Patient Satisfaction; Quality of Life; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia | 2017 |
7 trial(s) available for risperidone and chlorpromazine
Article | Year |
---|---|
A study of enhanced management in patients with treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Chlorpromazine; Drug Resistance; Female; Humans; Male; Psychiatric Status Rating Scales; Psychotherapy; Risperidone; Schizophrenia; Schizophrenic Psychology; Video Recording | 1997 |
Electroencephalographic and psychomotor effects of chlorpromazine and risperidone relative to placebo in normal healthy volunteers.
Topics: Adolescent; Adult; Antipsychotic Agents; Chlorpromazine; Cross-Over Studies; Double-Blind Method; Drug Interactions; Electroencephalography; Eye; Humans; Male; Psychomotor Performance; Risperidone; Sleep Stages; Time Factors | 1999 |
A prospective 4-5 year follow-up of juvenile onset bipolar disorder.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Chlorpromazine; Diagnostic and Statistical Manual of Mental Disorders; Drug Administration Schedule; Female; Follow-Up Studies; Haloperidol; Humans; Imipramine; Lithium Carbonate; Male; Phenotype; Prospective Studies; Recovery of Function; Risperidone; Secondary Prevention; Severity of Illness Index; Valproic Acid | 2004 |
A pharmaco-EEG study on antipsychotic drugs in healthy volunteers.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Cross-Over Studies; Dibenzothiazepines; Electroencephalography; Fourier Analysis; Haloperidol; Humans; Indoles; Isoindoles; Male; Olanzapine; Quetiapine Fumarate; Reference Values; Risperidone; Single-Blind Method; Thiazoles; Time Factors | 2007 |
Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders.
Topics: Antipsychotic Agents; Body Mass Index; Body Weight; Chlorpromazine; Female; Follow-Up Studies; Humans; Longitudinal Studies; Male; Prolactin; Psychotic Disorders; Risperidone; Sex Characteristics | 2007 |
Huperzine A as add-on therapy in patients with treatment-resistant schizophrenia: an open-labeled trial.
Topics: Adolescent; Adult; Aged; Alkaloids; Antipsychotic Agents; Chlorpromazine; Cholinesterase Inhibitors; Clozapine; Drug Resistance; Drug Synergism; Female; Humans; Male; Middle Aged; Risperidone; Schizophrenia; Sesquiterpenes | 2007 |
Ghrelin and leptin response to oral glucose challenge among antipsychotic drug-treated children.
Topics: Administration, Oral; Adolescent; Age Factors; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Blood Glucose; Body Mass Index; Child; Chlorpromazine; Fasting; Female; Ghrelin; Glucose; Glucose Tolerance Test; Humans; Insulin; Leptin; Male; Piperazines; Quinolones; Risperidone; Sex Factors; Time Factors; Weight Gain | 2007 |
88 other study(ies) available for risperidone and chlorpromazine
Article | Year |
---|---|
Pyrrole mannich bases as potential antipsychotic agents.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Male; Mannich Bases; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, Serotonin; Structure-Activity Relationship | 1992 |
Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors.
Topics: Animals; Antipsychotic Agents; Cell Line; Molecular Structure; Rats; Receptors, Serotonin | 1994 |
Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor.
Topics: Adenylyl Cyclases; Amino Acid Sequence; Animals; Antipsychotic Agents; Base Sequence; Brain Chemistry; Cell Line, Transformed; Chlorocebus aethiops; Chromosome Mapping; Chromosomes, Human, Pair 1; Cloning, Molecular; Clozapine; DNA, Complementary; Genes; Humans; Kinetics; Molecular Sequence Data; Open Reading Frames; Protein Conformation; Rats; Receptors, Serotonin; Recombinant Proteins; Sequence Alignment; Sequence Homology, Nucleic Acid; Serotonin Agents; Signal Transduction; Species Specificity | 1996 |
Creation of a constitutively activated state of the 5-hydroxytryptamine2A receptor by site-directed mutagenesis: inverse agonist activity of antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; COS Cells; Mutagenesis, Site-Directed; Phosphatidylinositols; Protein Conformation; Rats; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Serotonin; Serotonin Receptor Agonists; Structure-Activity Relationship | 1998 |
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.
Topics: Animals; Antipsychotic Agents; CHO Cells; Cricetinae; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Serotonin Agents; Sulfur Radioisotopes | 1998 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors.
Topics: Animals; Antipsychotic Agents; COS Cells; Dose-Response Relationship, Drug; Humans; Inositol Phosphates; Radioligand Assay; Receptor, Serotonin, 5-HT2C; Receptors, Serotonin; Serotonin Receptor Agonists | 2000 |
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water | 2001 |
In vitro P-glycoprotein affinity for atypical and conventional antipsychotics.
Topics: Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzodiazepines; Binding, Competitive; Clozapine; Dibenzothiazepines; Dose-Response Relationship, Drug; Humans; Kinetics; Olanzapine; Pirenzepine; Quetiapine Fumarate; Recombinant Proteins; Risperidone | 2002 |
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
Topics: Blood Proteins; Chemical Phenomena; Chemistry, Physical; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding | 2002 |
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
Topics: Anti-Arrhythmia Agents; Cation Transport Proteins; Cluster Analysis; Databases, Factual; Ether-A-Go-Go Potassium Channels; Long QT Syndrome; Models, Molecular; Molecular Conformation; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2002 |
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Discriminant Analysis; Drug Evaluation, Preclinical; Forecasting; Humans; Protein Binding; Receptors, Histamine H1; Statistics, Nonparametric; Weight Gain | 2003 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
A two-state homology model of the hERG K+ channel: application to ligand binding.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Ligands; Models, Biological; Models, Molecular; Potassium Channels, Voltage-Gated; Protein Binding; Protein Conformation | 2005 |
Stable expression of constitutively activated mutant h5HT6 and h5HT7 serotonin receptors: inverse agonist activity of antipsychotic drugs.
Topics: Amino Acid Substitution; Antipsychotic Agents; Cell Line; Cyclic AMP; Humans; Mutagenesis, Site-Directed; Mutation; Radioligand Assay; Receptors, Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Transfection | 2005 |
High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
Topics: Animals; Brain; Central Nervous System Agents; Dialysis; Hydrophobic and Hydrophilic Interactions; In Vitro Techniques; Mice; Models, Statistical; Protein Binding; Quantitative Structure-Activity Relationship; Rats | 2007 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzoxazines; Biogenic Monoamines; Humans; Hyperprolactinemia; Indoles; Metabolic Diseases; Phthalimides; Piperazines; Principal Component Analysis; Pyridines; Radioligand Assay; Receptors, Biogenic Amine; Weight Gain | 2007 |
BK Virus replication in vitro: limited effect of drugs interfering with viral uptake and intracellular transport.
Topics: Antiviral Agents; BK Virus; Cell Line; Chloroquine; Humans; Microbial Sensitivity Tests; Molecular Structure; Nystatin; Virus Replication | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
Topics: Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Models, Molecular; Potassium Channel Blockers; Quantitative Structure-Activity Relationship | 2009 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
Topics: Absorption; Albumins; Animals; Brain; Brain Chemistry; Cell Membrane; Chromatography, High Pressure Liquid; Drug Evaluation, Preclinical; In Vitro Techniques; Lipids; Male; Microdialysis; Pharmaceutical Preparations; Protein Binding; Rats; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Swine; Tissue Distribution | 2011 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
Topics: Action Potentials; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Computer Simulation; Dogs; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Guinea Pigs; HEK293 Cells; Humans; Ion Channels; Kinetics; Models, Cardiovascular; NAV1.5 Voltage-Gated Sodium Channel; Patch-Clamp Techniques; Potassium Channel Blockers; Rabbits; Risk Assessment; Risk Factors; Sodium Channel Blockers; Sodium Channels; Torsades de Pointes; Transfection | 2011 |
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
Topics: Cell Line, Tumor; Cryopreservation; Female; Hepatocytes; Humans; Male; Metabolic Clearance Rate; Pharmaceutical Preparations; Predictive Value of Tests | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
MICE models: superior to the HERG model in predicting Torsade de Pointes.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp Techniques; Predictive Value of Tests; Torsades de Pointes | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Avoidance Learning; Benzoxazoles; Catalepsy; CHO Cells; Cricetulus; Dementia; Dopamine D2 Receptor Antagonists; HEK293 Cells; Humans; Male; Models, Molecular; Motor Activity; Radioligand Assay; Rats, Wistar; Receptors, Serotonin; Serotonin Antagonists; Structure-Activity Relationship; Sulfonamides | 2014 |
Serotonin2 receptor-mediated excitation of interneurons in piriform cortex: antagonism by atypical antipsychotic drugs.
Topics: Action Potentials; Animals; Antipsychotic Agents; Bicuculline; Cerebral Cortex; Chlorpromazine; Clozapine; Electrophysiology; gamma-Aminobutyric Acid; Haloperidol; In Vitro Techniques; Interneurons; Isoxazoles; Male; Membrane Potentials; Piperidines; Pyramidal Cells; Rats; Rats, Sprague-Dawley; Risperidone; Serotonin Antagonists | 1994 |
Agitated behavior relieved following treatment of cervical dystonia in dementia.
Topics: Alzheimer Disease; Botulinum Toxins; Chlorpromazine; Dystonia; Female; Humans; Isoxazoles; Middle Aged; Neck Muscles; Phenytoin; Piperidines; Risperidone; Valproic Acid | 1995 |
Effects of atypical antipsychotic agents on social behavior in rodents.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Apomorphine; Benzazepines; Catalepsy; Chlorpromazine; Clozapine; Diazepam; Haloperidol; Isoxazoles; Male; Mice; Mice, Inbred Strains; Piperidines; Raclopride; Radioligand Assay; Rats; Rats, Wistar; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Serotonin; Risperidone; Salicylamides; Social Behavior | 1993 |
[A study on the pharmacological properties of atypical antipsychotic drugs: in vivo dopamine and serotonin receptor occupancy by atypical antipsychotic drugs in the rat brain].
Topics: Animals; Antipsychotic Agents; Autoradiography; Brain; Chlorpromazine; Clozapine; Dibenzothiepins; Flupenthixol; Haloperidol; In Vitro Techniques; Isoxazoles; Male; Piperidines; Pyrimidinones; Rats; Rats, Wistar; Receptors, Dopamine; Receptors, Serotonin; Risperidone | 1993 |
Olanzapine. Keep an eye on this neuroleptic.
Topics: Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Clinical Trials as Topic; Dopamine Antagonists; Double-Blind Method; Haloperidol; Humans; Olanzapine; Pirenzepine; Risperidone; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists | 2000 |
The discriminative stimulus properties of the atypical antipsychotic olanzapine in rats.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Clozapine; Discrimination Learning; Generalization, Psychological; Haloperidol; Male; Olanzapine; Pirenzepine; Raclopride; Rats; Rats, Sprague-Dawley; Risperidone; Ritanserin; Scopolamine | 2000 |
Differential effects of subchronic treatments with atypical antipsychotic drugs on dopamine D2 and serotonin 5-HT2A receptors in the rat brain.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain Chemistry; Chlorpromazine; Dopamine Antagonists; Dose-Response Relationship, Drug; Humans; Indoles; Isoindoles; Male; Olanzapine; Pirenzepine; Protein Binding; Quinolines; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Receptors, Serotonin; Risperidone; Selective Serotonin Reuptake Inhibitors; Thiazoles | 2000 |
Tardive dystonia provoked by concomitantly administered risperidone.
Topics: Adolescent; Antipsychotic Agents; Chlorpromazine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Hypotension; Middle Aged; Parkinson Disease, Secondary; Risperidone; Schizophrenia | 2000 |
Olanzapine: new preparation. Keep an eye on this neuroleptic.
Topics: Antipsychotic Agents; Chlorpromazine; Clinical Trials as Topic; Humans; Pirenzepine; Risperidone; Schizophrenia; Treatment Outcome | 1999 |
Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat.
Topics: Acetylcholine; Adrenergic alpha-Antagonists; Animals; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Clozapine; Dialysis Solutions; Dopamine Antagonists; Extracellular Space; Haloperidol; Hippocampus; Injections, Intraperitoneal; Injections, Subcutaneous; Male; Microdialysis; Olanzapine; Piperazines; Pirenzepine; Rats; Rats, Wistar; Risperidone; Serotonin Antagonists; Thiazoles; Thioridazine | 2002 |
Glucose intolerance with atypical antipsychotics.
Topics: Adverse Drug Reaction Reporting Systems; Antipsychotic Agents; Bayes Theorem; Benzodiazepines; Chlorpromazine; Clozapine; Diabetes Mellitus; Glucose Intolerance; Haloperidol; Humans; Hyperglycemia; Olanzapine; Pirenzepine; Risk Factors; Risperidone; World Health Organization | 2002 |
Discriminative stimulus properties in rats of the novel antipsychotic quetiapine.
Topics: Amisulpride; Analysis of Variance; Animals; Antipsychotic Agents; Chlorpromazine; Clozapine; Dibenzothiazepines; Discrimination Learning; Discrimination, Psychological; Dose-Response Relationship, Drug; Female; Generalization, Psychological; Haloperidol; Loxapine; Quetiapine Fumarate; Quinoxalines; Rats; Rats, Wistar; Risperidone; Sulpiride | 2002 |
Acute massive pulmonary thromboembolism associated with risperidone and conventional phenothiazines.
Topics: Adult; Aged; Antipsychotic Agents; Chlorpromazine; Dopamine Antagonists; Female; Humans; Japan; Male; Middle Aged; Phenothiazines; Pulmonary Embolism; Risperidone; Severity of Illness Index; Sex Distribution; Thromboembolism | 2003 |
alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brimonidine Tartrate; Chlorpromazine; CHO Cells; Clozapine; Cricetinae; Cyclic AMP; Dibenzothiazepines; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Gene Expression; Haloperidol; Humans; Isoxazoles; Norepinephrine; Olanzapine; Piperazines; Piperidines; Pirenzepine; Quetiapine Fumarate; Quinolones; Quinoxalines; Receptors, Adrenergic, alpha-2; Receptors, Dopamine D2; Risperidone; Thiazoles; Transfection; Yohimbine | 2003 |
Comparative behavioural effects of typical and atypical antipsychotic drugs in rhesus monkey.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Behavior, Animal; Chlorpromazine; Dose-Response Relationship, Drug; Drinking Behavior; Feeding Behavior; Female; Haloperidol; Injections, Intramuscular; Macaca mulatta; Male; Motor Activity; Risperidone; Social Behavior; Time Factors; Videotape Recording | 2003 |
Antipsychotics increase microtubule-associated protein 2 mRNA but not spinophilin mRNA in rat hippocampus and cortex.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Cerebral Cortex; Chlorpromazine; Clozapine; Gene Expression Regulation; Haloperidol; Hippocampus; In Situ Hybridization; Male; Microfilament Proteins; Microtubule-Associated Proteins; Nerve Tissue Proteins; Neurites; Olanzapine; Rats; Rats, Sprague-Dawley; Risperidone; RNA, Messenger; Tissue Distribution | 2004 |
Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Administration, Oral; Animals; Antipsychotic Agents; Basal Ganglia Diseases; Catalepsy; Chlorpromazine; Dibenzothiazepines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Haloperidol; Hyperkinesis; Injections, Intraperitoneal; Male; Methamphetamine; Mice; Piperazines; Pyridines; Quetiapine Fumarate; Receptor, Serotonin, 5-HT1A; Risperidone; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT1 Receptor Antagonists | 2004 |
Effects of amisulpride, risperidone and chlorpromazine on auditory and visual latent inhibition, prepulse inhibition, executive function and eye movements in healthy volunteers.
Topics: Acoustic Stimulation; Administration, Oral; Adult; Akathisia, Drug-Induced; Amisulpride; Blood Pressure; Chlorpromazine; Controlled Clinical Trials as Topic; Demography; Double-Blind Method; Eye Movements; Humans; Male; Neuropsychological Tests; Photic Stimulation; Problem Solving; Reaction Time; Reflex, Startle; Risperidone; Space Perception; Sulpiride; Verbal Behavior | 2004 |
Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: population-based study.
Topics: Adult; Age Factors; Aged; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Chlorpromazine; Dopamine Antagonists; Drug Administration Schedule; Family Practice; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Risperidone; Schizophrenia; Sex Factors | 2005 |
[No association of -1438G/A polymorphism in promoter region of 5-HT2A receptor gene with antipsychotic agent-induced weight gain].
Topics: Adult; Antipsychotic Agents; Chlorpromazine; Female; Gene Frequency; Genotype; Humans; Male; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Promoter Regions, Genetic; Receptor, Serotonin, 5-HT2A; Risperidone; Schizophrenia; Weight Gain | 2005 |
Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain-Derived Neurotrophic Factor; Chlorpromazine; Corpus Striatum; Haloperidol; Hippocampus; Male; Nerve Growth Factor; Olanzapine; Rats; Rats, Wistar; Risperidone; Time | 2006 |
Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Chlorpromazine; Clozapine; Cross-Over Studies; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Haloperidol; Lipid Peroxidation; Male; Membrane Lipids; Olanzapine; Rats; Rats, Wistar; Risperidone; Schizophrenia; Superoxide Dismutase | 2007 |
Prototypical antipsychotic drugs protect hippocampal neuronal cultures against cell death induced by growth medium deprivation.
Topics: Animals; Anisoles; Antipsychotic Agents; Benzazepines; Butaclamol; Caspase Inhibitors; Cell Death; Cells, Cultured; Chlorpromazine; Clozapine; Domperidone; Dopamine Antagonists; Excitatory Amino Acid Antagonists; Ginkgo biloba; Haloperidol; Hippocampus; Indans; Isoxazoles; Neurons; Neuroprotective Agents; Peptides; Piperidines; Plant Extracts; Propylamines; Raclopride; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Receptors, N-Methyl-D-Aspartate; Remoxipride; Risperidone; Sulpiride | 2006 |
Priapism associated with typical and atypical antipsychotic medications.
Topics: Adrenergic alpha-Antagonists; Adult; Antipsychotic Agents; Chlorpromazine; Humans; Male; Priapism; Risperidone; Schizophrenia | 2006 |
Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein.
Topics: Animals; Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzodiazepines; Chlorpromazine; Clozapine; Cyclosporins; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Interactions; Flow Cytometry; Fluorescent Dyes; Haloperidol; Isoxazoles; Kidney; Liver; LLC-PK1 Cells; Olanzapine; Paliperidone Palmitate; Pyrimidines; Quetiapine Fumarate; Rhodamine 123; Risperidone; Swine; Transfection | 2006 |
Relative risk of glucose elevation during antipsychotic exposure in a Veterans Administration population.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Chlorpromazine; Cohort Studies; Female; Fluphenazine; Haloperidol; Hospitals, Veterans; Humans; Hyperglycemia; Incidence; Male; Middle Aged; Olanzapine; Perphenazine; Retrospective Studies; Risk Assessment; Risk Factors; Risperidone; Southeastern United States; Time Factors; Veterans | 2007 |
Comparative neurochemical changes associated with chronic administration of typical and atypical neuroleptics: implications in tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Body Weight; Chlorpromazine; Clozapine; Dopamine; Dyskinesia, Drug-Induced; Haloperidol; Male; Norepinephrine; Prosencephalon; Rats; Rats, Wistar; Risperidone; Serotonin | 2007 |
Neuroleptic malignant syndrome and catatonia in a patient with dementia.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Catatonia; Chlorpromazine; Cholinesterase Inhibitors; Cognition Disorders; Creatine Kinase; Dementia; Disease Progression; Donepezil; Female; Humans; Indans; Lorazepam; Muscle Rigidity; Neuroleptic Malignant Syndrome; Olanzapine; Piperidines; Recurrence; Risperidone | 2008 |
Acute respiratory distress due to antipsychotic drugs.
Topics: Adult; Antiparkinson Agents; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Drug Therapy, Combination; Dystonia; Fatal Outcome; Haloperidol; Humans; Larynx; Male; Olanzapine; Respiratory Distress Syndrome; Respiratory Insufficiency; Risperidone; Schizophrenia | 2010 |
Contributions to the study of morphofunctional interrelations in the liver of the rats treated with certain antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Chlorpromazine; Haloperidol; Liver; Male; Rats; Rats, Wistar; Risperidone | 2011 |
Risperidone-induced Pisa syndrome in MS: resolution with lurasidone and recurrence with Chlorpromazine.
Topics: Adult; Antipsychotic Agents; Child Development Disorders, Pervasive; Chlorpromazine; Gait Ataxia; Humans; Isoindoles; Lurasidone Hydrochloride; Male; Multiple Sclerosis; Recurrence; Risperidone; Syndrome; Thiazoles | 2013 |
Adverse effects of antipsychotics on micro-vascular endothelial cells of the human blood-brain barrier.
Topics: Antipsychotic Agents; Apoptosis; Blood-Brain Barrier; Capillary Permeability; Caspase 3; Caspase 8; Caspase 9; Cell Survival; Cells, Cultured; Chlorpromazine; Clozapine; DNA Breaks; Endothelial Cells; Haloperidol; Humans; Microvessels; Oxidative Stress; Reactive Oxygen Species; Risperidone | 2014 |
A systematic microdialysis study of dopamine transmission in the accumbens shell/core and prefrontal cortex after acute antipsychotics.
Topics: Administration, Intravenous; Animals; Antipsychotic Agents; Chlorpromazine; Clozapine; Dopamine; Haloperidol; Male; Microdialysis; Nucleus Accumbens; Prefrontal Cortex; Raclopride; Rats; Rats, Sprague-Dawley; Risperidone; Time Factors | 2015 |
A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Cost-Benefit Analysis; Drug Costs; Haloperidol; Health Care Costs; Humans; Middle Aged; Olanzapine; Quality-Adjusted Life Years; Risperidone; Schizophrenia; Uganda | 2015 |
Association studies of genomic variants with treatment response to risperidone, clozapine, quetiapine and chlorpromazine in the Chinese Han population.
Topics: Adolescent; Adult; Antipsychotic Agents; Asian People; Chi-Square Distribution; China; Chlorpromazine; Clozapine; Cross-Sectional Studies; Female; Genetic Association Studies; Haplotypes; Humans; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Pharmacogenomic Testing; Pharmacogenomic Variants; Phenotype; Polymorphism, Single Nucleotide; Predictive Value of Tests; Quetiapine Fumarate; Reelin Protein; Risk Factors; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Young Adult | 2016 |
Risperidone, quetiapine and chlorpromazine may have induced priapism in an adolescent.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Chlorpromazine; Drug Therapy, Combination; Humans; Male; Penis; Priapism; Quetiapine Fumarate; Risperidone; Ultrasonography, Doppler | 2016 |
Risk of Mortality Among Patients Treated With Antipsychotic Medications: A Nationwide Population-Based Study in Taiwan.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Chlorpromazine; Critical Illness; Female; Follow-Up Studies; Haloperidol; Humans; Male; Middle Aged; Mortality; Proportional Hazards Models; Quetiapine Fumarate; Retrospective Studies; Risk Factors; Risperidone; Taiwan; Time Factors; Young Adult | 2016 |
Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: Results of a 2-year prospective study, including an additional 1-year follow-up.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Chlorpromazine; Delayed-Action Preparations; Dopamine; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Injections; Male; Middle Aged; Prospective Studies; Psychiatric Status Rating Scales; Psychoses, Substance-Induced; Receptors, Dopamine D2; Risperidone; Schizophrenia; Young Adult | 2016 |
Different influence of antipsychotics on the balance between pro- and anti-inflammatory cytokines depends on glia activation: An in vitro study.
Topics: Animals; Antipsychotic Agents; Cell Differentiation; Cell Survival; Cells, Cultured; Chlorpromazine; Culture Media; Cytokines; Haloperidol; In Vitro Techniques; Inflammation; Interleukin-10; Interleukin-1beta; Lipopolysaccharides; Neuroglia; Rats; Risperidone; Tumor Necrosis Factor-alpha | 2017 |
Risperidone versus olanzapine in the acute treatment of Persistent Delusional Disorder: A retrospective analysis.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Female; Humans; Logistic Models; Male; Middle Aged; Olanzapine; Prospective Studies; Retrospective Studies; Risperidone; Schizophrenia, Paranoid; Treatment Outcome | 2017 |
The role of oxidative stress in antipsychotics induced ovarian toxicity.
Topics: Animals; Antipsychotic Agents; Caspases; Cell Survival; Cells, Cultured; Chlorpromazine; Clozapine; Female; Glutathione; Haloperidol; Oxidative Stress; Rats, Sprague-Dawley; Reactive Oxygen Species; Risperidone; Theca Cells | 2017 |
Clozapine, chlorpromazine and risperidone dose-dependently reduce emotional hyperthermia, a biological marker of salience.
Topics: Animals; Arousal; Chlorpromazine; Clozapine; Dose-Response Relationship, Drug; Emotions; Fever; Male; Rats; Rats, Sprague-Dawley; Risperidone; Thermogenesis; Vasoconstriction | 2017 |
Anticholinergic Load and Nutritional Status in Older Individuals.
Topics: Aged; Aged, 80 and over; Chlorpromazine; Cholinergic Antagonists; Female; Geriatric Assessment; Haloperidol; Hospitalization; Humans; Hydroxyzine; Japan; Linear Models; Longitudinal Studies; Male; Malnutrition; Metoclopramide; Multivariate Analysis; Nutrition Assessment; Nutritional Status; Patient Discharge; Regression Analysis; Retrospective Studies; Risperidone | 2020 |
Serotonin 2A (5-HT
Topics: Amphetamines; Animals; Antipsychotic Agents; Cell-Matrix Junctions; Chlorpromazine; HEK293 Cells; Humans; Mental Disorders; Olanzapine; Rats; Receptor, Serotonin, 5-HT2A; Risperidone; Serotonin; Serotonin 5-HT2 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Stress Fibers | 2020 |
Prevalence of antipsychotic-induced extrapyramidal symptoms and their association with neurocognition and social cognition in outpatients with schizophrenia in the "real-life".
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Cognition; Female; Humans; Male; Middle Aged; Prevalence; Risperidone; Schizophrenia; Schizophrenic Psychology; Social Cognition | 2021 |
A Case Report of Stuttering Induced by Risperidone and Chlorpromazine.
Topics: Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Haloperidol; Humans; Male; Risperidone; Stuttering | 2022 |
Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
Topics: Adenosine Monophosphate; Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chlorpromazine; Clopenthixol; Clozapine; Flupenthixol; Fluphenazine; Haloperidol; Humans; Olanzapine; Paliperidone Palmitate; Pharmaceutical Preparations; Pimozide; Quetiapine Fumarate; Risperidone; Sulpiride; Trifluoperazine | 2022 |